Procept BioRobotics Faces Class Action Over Inventory Discrepancies

The litigation, filed as Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, centers on allegations that the company misled shareholders regarding its U.S. handpiece sales. While management previously claimed sales figures aligned with procedural usage, a February 25, 2026, earnings release revealed a massive inventory glut. Procept admitted that handpiece sales had consistently outpaced procedures since early 2023, resulting in an accumulation of more than 10,000 excess units in the field.

This inventory imbalance forced a stark correction in the company's financial performance. Quarterly U.S. handpiece sales plummeted from 13,225 units in the third quarter to 9,400, a sequential decline of nearly 30%. The company subsequently missed its annual revenue guidance by tens of millions of dollars. Investors reacted to the news by selling off shares, driving the price down from $27.84 to $22.69 over two days of trading. The law firm Kahn Swick & Foti, LLC is currently representing investors seeking recovery for losses sustained during this period.